Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics.
Abecasis AB, Wensing AM, Paraskevis D, Vercauteren J, Theys K, Van de Vijver DA, Albert J, Asjö B, Balotta C, Beshkov D, Camacho RJ, Clotet B, De Gascun C, Griskevicius A, Grossman Z, Hamouda O, Horban A, Kolupajeva T, Korn K, Kostrikis LG, Kücherer C, Liitsola K, Linka M, Nielsen C, Otelea D, Paredes R, Poljak M, Puchhammer-Stöckl E, Schmit JC, Sönnerborg A, Stanekova D, Stanojevic M, Struck D, Boucher CA, Vandamme AM. Abecasis AB, et al. Among authors: van de vijver da, de gascun c. Retrovirology. 2013 Jan 14;10:7. doi: 10.1186/1742-4690-10-7. Retrovirology. 2013. PMID: 23317093 Free PMC article.
The BAF complex inhibitor pyrimethamine reverses HIV-1 latency in people with HIV-1 on antiretroviral therapy.
Prins HAB, Crespo R, Lungu C, Rao S, Li L, Overmars RJ, Papageorgiou G, Mueller YM, Stoszko M, Hossain T, Kan TW, Rijnders BJA, Bax HI, van Gorp ECM, Nouwen JL, de Vries-Sluijs TEMS, Schurink CAM, de Mendonça Melo M, van Nood E, Colbers A, Burger D, Palstra RJ, van Kampen JJA, van de Vijver DAMC, Mesplède T, Katsikis PD, Gruters RA, Koch BCP, Verbon A, Mahmoudi T, Rokx C. Prins HAB, et al. Among authors: van de vijver damc. Sci Adv. 2023 Mar 17;9(11):eade6675. doi: 10.1126/sciadv.ade6675. Epub 2023 Mar 15. Sci Adv. 2023. PMID: 36921041 Free PMC article. Clinical Trial.
Rising prevalence of HIV-1 non-B subtypes in Belgium: 1983-2001.
Snoeck J, Van Laethem K, Hermans P, Van Wijngaerden E, Derdelinckx I, Schrooten Y, van de Vijver DA, De Wit S, Clumeck N, Vandamme AM. Snoeck J, et al. Among authors: de wit s, van laethem k, van wijngaerden e, van de vijver da. J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):279-85. doi: 10.1097/00126334-200403010-00009. J Acquir Immune Defic Syndr. 2004. PMID: 15076243
An automated genotyping system for analysis of HIV-1 and other microbial sequences.
de Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, Seebregts C, Snoeck J, van Rensburg EJ, Wensing AM, van de Vijver DA, Boucher CA, Camacho R, Vandamme AM. de Oliveira T, et al. Among authors: van rensburg ej, van de vijver da. Bioinformatics. 2005 Oct 1;21(19):3797-800. doi: 10.1093/bioinformatics/bti607. Epub 2005 Aug 2. Bioinformatics. 2005. PMID: 16076886
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management.
Wensing AM, van de Vijver DA, Angarano G, Asjö B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hemmer R, Hoepelman A, Horban A, Korn K, Kücherer C, Leitner T, Loveday C, MacRae E, Maljkovic I, de Mendoza C, Meyer L, Nielsen C, Op de Coul EL, Ormaasen V, Paraskevis D, Perrin L, Puchhammer-Stöckl E, Ruiz L, Salminen M, Schmit JC, Schneider F, Schuurman R, Soriano V, Stanczak G, Stanojevic M, Vandamme AM, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M, Boucher CA; SPREAD Programme. Wensing AM, et al. Among authors: de mendoza c, de luca a, van laethem k, van de vijver da. J Infect Dis. 2005 Sep 15;192(6):958-66. doi: 10.1086/432916. Epub 2005 Aug 15. J Infect Dis. 2005. PMID: 16107947
The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes.
van de Vijver DA, Wensing AM, Angarano G, Asjö B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hemmer R, Hoepelman A, Horban A, Korn K, Kücherer C, Leitner T, Loveday C, MacRae E, Maljkovic I, de Mendoza C, Meyer L, Nielsen C, Op de Coul EL, Ormaasen V, Paraskevis D, Perrin L, Puchhammer-Stöckl E, Ruiz L, Salminen M, Schmit JC, Schneider F, Schuurman R, Soriano V, Stanczak G, Stanojevic M, Vandamme AM, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M, Boucher CA. van de Vijver DA, et al. Among authors: de mendoza c, de luca a, van laethem k. J Acquir Immune Defic Syndr. 2006 Mar;41(3):352-60. doi: 10.1097/01.qai.0000209899.05126.e4. J Acquir Immune Defic Syndr. 2006. PMID: 16540937
Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.
Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, Heneine W, Kantor R, Jordan MR, Schapiro JM, Vandamme AM, Sandstrom P, Boucher CA, van de Vijver D, Rhee SY, Liu TF, Pillay D, Shafer RW. Bennett DE, et al. PLoS One. 2009;4(3):e4724. doi: 10.1371/journal.pone.0004724. Epub 2009 Mar 6. PLoS One. 2009. PMID: 19266092 Free PMC article.
128 results